Literature DB >> 29688870

Drug coverage in Canada: gaps and opportunities.

Fiona Clement1, Katherine A Memedovich1.   

Abstract

Mesh：

Year:  2018        PMID： 29688870      PMCID： PMC5915235          DOI： 10.1503/jpn.180051

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN： 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  6 in total

1.  Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010.

Authors:  Jamie R Daw; Steven G Morgan
Journal:  Health Policy       Date:  2011-10-05       Impact factor: 2.980

Review 2.  Optimizing the use of prescription drugs in Canada through the Common Drug Review.

Authors:  Mike Tierney; Braden Manns
Journal:  CMAJ       Date:  2008-02-12       Impact factor: 8.262

3.  Estimated cost of universal public coverage of prescription drugs in Canada.

Authors:  Steven G Morgan; Michael Law; Jamie R Daw; Liza Abraham; Danielle Martin
Journal:  CMAJ       Date:  2015-03-16       Impact factor: 8.262

4.  Comparison of Canadian public medication insurance plans and the impact on out-of-pocket costs.

Authors:  David J T Campbell; Braden J Manns; Lesley J J Soril; Fiona Clement
Journal:  CMAJ Open       Date:  2017-11-22

5.  The consequences of patient charges for prescription drugs in Canada: a cross-sectional survey.

Authors:  Michael R Law; Lucy Cheng; Ashra Kolhatkar; Laurie J Goldsmith; Steven G Morgan; Anne M Holbrook; Irfan A Dhalla
Journal:  CMAJ Open       Date:  2018-02-05

Review 6.  A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development.

Authors:  Lianne Barnieh; Fiona Clement; Anthony Harris; Marja Blom; Cam Donaldson; Scott Klarenbach; Don Husereau; Diane Lorenzetti; Braden Manns
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240
  6 in total
  3 in total

1.  After More Than 50 Years, Pharmacare (and Dental Care) are Coming to Canada.

Authors:  Joel Lexchin
Journal:  Int J Health Serv       Date:  2022-05-09       Impact factor: 1.851

2.  Cost-related medication nonadherence in Canada: a systematic review of prevalence, predictors, and clinical impact.

Authors:  Anne M Holbrook; Mei Wang; Munil Lee; Zhiyuan Chen; Michael Garcia; Laura Nguyen; Angela Ford; Selina Manji; Michael R Law
Journal:  Syst Rev       Date:  2021-01-06

Review 3.  Not All Canadian Cancer Patients Are Equal-Disparities in Public Cancer Drug Funding across Canada.

Authors:  Ceilidh MacPhail; Stephanie Snow
Journal:  Curr Oncol       Date:  2022-03-17       Impact factor: 3.677
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.